Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Targeting oncogenic Ras signaling in hematologic malignancies.

Ward AF, Braun BS, Shannon KM.

Blood. 2012 Oct 25;120(17):3397-406. doi: 10.1182/blood-2012-05-378596. Epub 2012 Aug 16. Review.

2.

Ras processing as a therapeutic target in hematologic malignancies.

Le DT, Shannon KM.

Curr Opin Hematol. 2002 Jul;9(4):308-15. Review.

PMID:
12042705
3.

Tailoring Ras-pathway--inhibitor combinations for cancer therapy.

Blum R, Kloog Y.

Drug Resist Updat. 2005 Dec;8(6):369-80. Epub 2005 Dec 13. Review.

PMID:
16356760
4.

Approaches to Ras signaling modulation and treatment of Ras-dependent disorders: a patent review (2007--present).

Sacco E, Spinelli M, Vanoni M.

Expert Opin Ther Pat. 2012 Nov;22(11):1263-87. doi: 10.1517/13543776.2012.728586. Epub 2012 Sep 26. Review.

PMID:
23009088
5.

Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.

Zhu N, Xiao H, Wang LM, Fu S, Zhao C, Huang H.

Future Oncol. 2015;11(4):659-73. doi: 10.2217/fon.14.280. Review.

PMID:
25686120
6.

Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies?

Reuter CW, Morgan MA, Bergmann L.

Blood. 2000 Sep 1;96(5):1655-69. Review.

7.

Improving Prospects for Targeting RAS.

Singh H, Longo DL, Chabner BA.

J Clin Oncol. 2015 Nov 1;33(31):3650-9. doi: 10.1200/JCO.2015.62.1052. Epub 2015 Sep 14. Review.

PMID:
26371146
8.

The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.

Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y.

Clin Cancer Res. 2006 Sep 15;12(18):5533-42.

PMID:
17000690
9.

Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways.

Lackner MR.

Expert Rev Mol Diagn. 2010 Jan;10(1):75-87. doi: 10.1586/erm.09.78. Review.

PMID:
20014924
10.

Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor.

Cichowski K, Santiago S, Jardim M, Johnson BW, Jacks T.

Genes Dev. 2003 Feb 15;17(4):449-54.

11.

PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies.

De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, Clapp W, Bradner J, Vidaud M, Upadhyaya M, Legius E, Cichowski K.

Nature. 2014 Oct 9;514(7521):247-51. doi: 10.1038/nature13561. Epub 2014 Aug 13.

PMID:
25119042
12.

Ras as a therapeutic target in hematologic malignancies.

Alvarado Y, Giles FJ.

Expert Opin Emerg Drugs. 2007 May;12(2):271-84. Review.

PMID:
17604501
13.

Targeting ROR1 identifies new treatment strategies in hematological cancers.

Karvonen H, Niininen W, Murumägi A, Ungureanu D.

Biochem Soc Trans. 2017 Apr 15;45(2):457-464. doi: 10.1042/BST20160272. Review.

PMID:
28408486
14.

Ras family signaling: therapeutic targeting.

Cox AD, Der CJ.

Cancer Biol Ther. 2002 Nov-Dec;1(6):599-606. Review.

PMID:
12642680
15.

'Pathway drug cocktail': targeting Ras signaling based on structural pathways.

Nussinov R, Tsai CJ, Mattos C.

Trends Mol Med. 2013 Nov;19(11):695-704. doi: 10.1016/j.molmed.2013.07.009. Epub 2013 Aug 15. Review.

PMID:
23953481
16.

Differential oncogenic Ras signaling and senescence in tumor cells.

Bihani T, Mason DX, Jackson TJ, Chen SC, Boettner B, Lin AW.

Cell Cycle. 2004 Sep;3(9):1201-7. Epub 2004 Sep 5.

PMID:
15492501
17.

Blocking oncogenic Ras signaling for cancer therapy.

Adjei AA.

J Natl Cancer Inst. 2001 Jul 18;93(14):1062-74. Review.

PMID:
11459867
18.

Role of farnesyltransferase inhibitors in hematologic malignancies.

Santos ES, Rosenblatt JD, Goodman M.

Expert Rev Anticancer Ther. 2004 Oct;4(5):843-56. Review.

PMID:
15485318
19.

Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.

Xu J, Hedberg C, Dekker FJ, Li Q, Haigis KM, Hwang E, Waldmann H, Shannon K.

Blood. 2012 Jan 26;119(4):1032-5. doi: 10.1182/blood-2011-06-358960. Epub 2011 Dec 5.

20.

[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].

Müller-Tidow C, Steur C, Mizuki M, Schwäble J, Brandts C, Berdel WE, Serve H.

Dtsch Med Wochenschr. 2002 Oct 18;127(42):2195-200. German.

PMID:
12397548

Supplemental Content

Support Center